Skip to main content
. 2022 Sep 8;7(17):e160674. doi: 10.1172/jci.insight.160674

Figure 6. hCAR19 Tregs reduce aGVHD severity and improve overall survival in an hCD19-dependent manner.

Figure 6

(A) Percentage suppression by NT, tEGFR, or hCAR19 Tregs of CD8+ T cells in the presence of WT or hCD19-containing B cells. (B) Survival for hCD19TGTg/0 recipient mice after undergoing a lethal irradiation prior to receiving 5 × 106 BALB/c BM; BM with 2.5 × 106 Tcons; or BM with Tcons and either 1.25 × 106 hCAR19 or tEGFR Tregs; or WT C57BL/6 recipient mice receiving BALB/c BM with Tcons and hCAR19 Tregs (hCAR19 Treg, WTR). BM, n = 5; Tcons, n = 8; tEGFR Tregs, n = 6; hCAR19 Tregs, n = 6; hCAR19 Treg, WTR, n = 5. Data are representative from 4 independent experiments. (C and D) Clinical GVHD scores: 0, no disease; 10, severe disease. (C) Clinical GVHD scores quantified on day 33. (E) Percentage body weight quantified on day 33. (F) Percentage body weight. Student’s t test with Bonferroni correction for multiple comparisons was used for statistical analysis of weights and clinical scores. Log rank test was used to analyze survival curves. Error bars indicate the standard deviation of the mean. *:<0.5; **: <0.01; ***:<0.001; ****:<0.0001.